NCT01195792View on ClinicalTrials.gov

A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Obesity
Interventions
DRUG

GSK1521498

GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly

DRUG

Placebo

Placebo will be given for up to 35 days and subjects will be assessed weekly

Trial Locations (3)

CB2 0QQ

GSK Investigational Site, Cambridge

B15 3ES

GSK Investigational Site, Birmingham

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY